DDAVP (NEEDS NO REFRIGERATION)
Clinical safety rating
cautionComprehensive clinical and safety monograph for DDAVP (NEEDS NO REFRIGERATION) (DDAVP (NEEDS NO REFRIGERATION)).
Comprehensive clinical and safety monograph for DDAVP (NEEDS NO REFRIGERATION) (DDAVP (NEEDS NO REFRIGERATION)).
Central diabetes insipidusNocturnal enuresisHemophilia A with factor VIII levels >5%Von Willebrand disease (type I)
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that acts on V2 receptors in renal collecting ducts to increase water reabsorption and concentrate urine. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor activation on endothelial cells.
| Metabolism | Desmopressin undergoes limited hepatic metabolism via reduction of the disulfide bond; primarily excreted unchanged in urine. |
| Excretion | Primarily renal (approximately 60-70% excreted unchanged in urine); minimal biliary/fecal elimination (<5%). |
| Half-life | Terminal elimination half-life is 1.5-3 hours for intravenous and oral routes; increased to 3-5 hours in patients with renal impairment. |
| Protein binding | Low; approximately 0-1% bound to plasma proteins; negligible binding to albumin or other proteins. |
| Volume of Distribution | Approximately 0.3-0.5 L/kg; reflects distribution primarily into extracellular fluid with limited tissue penetration. |
| Bioavailability | Oral: ~0.5% (range 0.1-1%) due to extensive gastrointestinal degradation; Intranasal: ~3-5% (range 2-10%); Intravenous: 100%. |
| Onset of Action | Oral: 15-30 minutes; Intranasal: 10-20 minutes; Intravenous: within 5 minutes. |
| Duration of Action | Oral: 6-8 hours; Intranasal: 8-12 hours; Intravenous: 4-6 hours. Duration may vary with dose and indication; antidiuretic effect persists longer than vasopressor effect. |
| Molecular Weight | 1183.34 |
1-2 mg orally twice daily for central diabetes insipidus; intranasal 10-40 mcg/day in 1-3 divided doses; IV/SC 0.5-2 mcg/day in divided doses for diabetes insipidus.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for GFR >30 mL/min; for GFR 10-30 mL/min, reduce dose by 50%; avoid use if GFR <10 mL/min. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential fluid retention. |
| Pediatric use | Diabetes insipidus: oral 0.05 mg/kg/day in 2 divided doses; intranasal 5-30 mcg/day; IV/SC 0.1-1 mcg/day. Hemophilia A: IV 0.3 mcg/kg every 12-24 hours for 2-3 days. |
| Geriatric use | Start at low end of dosing range due to increased risk of hyponatremia and fluid overload; monitor serum sodium closely. |
| 1st trimester | Desmopressin does not cross the placenta in significant amounts. Limited human data show no increased risk of major birth defects. Use only if clearly needed. |
| 2nd trimester | No evidence of fetal harm in animal studies. Use if benefit outweighs risk. |
| 3rd trimester | Can be used for diabetes insipidus or nocturnal enuresis; monitor for hyponatremia and uterine hypertonicity. |
Clinical note
Comprehensive clinical and safety monograph for DDAVP (NEEDS NO REFRIGERATION) (DDAVP (NEEDS NO REFRIGERATION)).
| Placental transfer | Minimal placental transfer; not detectable in fetal circulation at therapeutic doses. |
| Breastfeeding | Desmopressin is excreted into breast milk in very low amounts, unlikely to affect the infant. Use caution with high doses. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Desmopressin (DDAVP) is classified as FDA Pregnancy Category B. No teratogenic effects have been observed in animal studies. There are no adequate and well-controlled studies in pregnant women. In human case reports, desmopressin use during pregnancy has not been associated with an increased risk of major birth defects, miscarriage, or adverse fetal outcomes. Theoretical risk of hyponatremia and seizures in the fetus if maternal hyponatremia occurs. Use during first trimester is generally considered low risk, but caution is advised. Second and third trimester: no specific fetal risks identified beyond those related to maternal hyponatremia. |
| Fetal Monitoring | Monitor maternal serum sodium levels, fluid balance, and urine output. In pregnancy, monitor blood pressure and signs of preeclampsia. Assess for symptoms of hyponatremia (headache, nausea, confusio). Fetal monitoring: standard fetal growth scans and non-stress tests as clinically indicated for underlying condition (e.g., diabetes insipidus). |
| Fertility Effects | No known direct effects on fertility in males or females. Desmopressin is used for diabetes insipidus and nocturnal enuresis; underlying conditions may affect fertility, but drug itself has no established impact on reproductive function. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to desmopressinModerate to severe renal impairment (CrCl <50 mL/min)HyponatremiaCardiac disease requiring diuretics
| Precautions | Hyponatremia and water intoxication, especially in patients with fluid/electrolyte imbalances or those on medications increasing ADH effect, Increased risk of thrombotic events (e.g., stroke, MI) in predisposed patients, Fluid restriction advised to prevent hyponatremia |
| Food/Dietary | No significant food interactions. However, fluid intake should be carefully monitored to avoid water intoxication. Avoid excessive alcohol or caffeine intake, as they may interfere with antidiuretic effect. |
| Clinical Pearls | DDAVP (desmopressin) is a synthetic analog of vasopressin that does not require refrigeration, allowing for convenient storage and travel. It is available as oral tablets, nasal spray, and injectable forms. Monitor for hyponatremia, especially in elderly patients or those with fluid overload. Avoid use in patients with primary polydipsia or severe renal impairment. For nocturnal enuresis, limit fluid intake 1 hour before bedtime to reduce the risk of water intoxication. In hemophilia A or von Willebrand disease, DDAVP can transiently increase factor VIII and vWF levels; however, tachyphylaxis may occur after repeated doses. |
| Patient Advice | Store DDAVP at room temperature (below 77°F/25°C); it does not need refrigeration. · Avoid drinking large amounts of water or other fluids unless thirsty to prevent low sodium levels (hyponatremia). · Take the last dose at bedtime for bedwetting to reduce nighttime urine production. · Inform your doctor if you experience headache, nausea, confusion, or weight gain, as these may be signs of hyponatremia. · Do not change dosing or frequency without consulting your healthcare provider. |
Loading safety data…